529508-58-5

Basic information

• Product Name: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole
• Synonyms: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole;1H-Indazole, 1-[(3-fluorophenyl)methyl]-5-nitro-;1-(3-Fluorobenzyl)-5-nitro-1H-indazole
• CAS NO: 529508-58-5
• Molecular Formula: C₁₄H₁₀FN₃O₂
• Molecular Weight: 271.25
• Product Categories: API intermediates
• Mol File: 529508-58-5.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 447.697°C at 760 mmHg
• Flash Point: 224.559°C
• Appearance: /
• Density: 1.382g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.82±0.30(Predicted)
• CAS DataBase Reference: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole(529508-58-5)
• EPA Substance Registry System: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole(529508-58-5)

Safety Data

• Hazardous Substances Data: 529508-58-5(Hazardous Substances Data)

Usage

General Description

1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole is a chemical compound with the molecular formula C14H10FN3O2. It is a member of the indazole class of organic compounds, which are commonly used in medicinal and pharmaceutical research. This specific compound contains a 3-fluorophenylmethyl group and a nitro group attached to the indazole ring, giving it potential bioactivity and pharmacological properties. The compound's structure suggests that it may be used in the development of new drugs, particularly in the field of antifungal or antimicrobial agents. Further research and testing would be needed to fully understand the potential applications and effects of 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole in pharmaceutical or biomedical settings.

InChI:InChI=1/C14H10FN3O2/c15-12-3-1-2-10(6-12)9-17-14-5-4-13(18(19)20)7-11(14)8-16-17/h1-8H,9H2

Upstream product

• 456-42-8 m-fluorobenzyl chloride 
• 5401-94-5 5-nitroindazole 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 

Downstream Products

• 856667-80-6 4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 856667-79-3 ethyl 4-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 914308-85-3 {5-cyano-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidin-4-ylsulfanyl}-acetic acidethyl ester 
• 914308-84-2 4-chloro-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidine-5-carbonitrile 
• 1338250-46-6 C₂₉H₂₆FN₇ 
• 1338250-42-2 C₃₀H₂₆FN₇ 
• 1338250-38-6 C₂₉H₂₄FN₇O 
• 202197-31-7 1-(3-fluorobenzyl)-1H-indazol-5-ylamine 
• 1353644-68-4 (3aR,6aR)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3 ,4-b]pyrrole-5(1 H)-carboxamide 
• 1353644-76-4 C₃₀H₂₃FN₆O₃ 
• 897025-61-5 N⁴-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxyquinazoline-4,6-diamine 

Relevant articles and documents

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

QUINAZOLINE COMPOUNDS

Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compounds can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.